{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:23Z","timestamp":1793946503532,"version":"4.8.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.semarthrit.2025.152786","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:44:19Z","timestamp":1752680659000},"page":"152786","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["CAR T-cell therapy in SLE: A systematic review"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9763-8209","authenticated-orcid":false,"given":"Alberto","family":"Nordmann-Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Geraldino-Pardilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniya","family":"Gartshteyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Souvignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-5023","authenticated-orcid":false,"given":"Anca","family":"Askanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.semarthrit.2025.152786_bib0001","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152786_bib0002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"22","key":"10.1016\/j.semarthrit.2025.152786_bib0003","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152786_bib0004","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152786_bib0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0006","article-title":"Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation","volume":"14","author":"Netsrithong","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152786_bib0007","first-page":"24","article-title":"Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells","volume":"7","author":"Ueda","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0008","unstructured":"FDA Approves Obe-cel for B-cell acute lymphoblastic leukemia (ALL) [press release]. November 11, 2024 2024."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102873","article-title":"B cell-targeted therapies in systemic lupus erythematosus","volume":"132","author":"Arbitman","year":"2022","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152786_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/cmi.2012.64","article-title":"B-cell-targeted therapies in systemic lupus erythematosus","volume":"10","author":"Chan","year":"2013","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152786_bib0011","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152786_bib0012","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152786_bib0014","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0015","unstructured":"Positive phase III results for Genentech\u2019s Gazyva show superiority to standard therapy alone in people with Lupus Nephritis [press release]. Sep 25, 2024 2024."},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152786_bib0016","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for Scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0017","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1182\/blood-2023-186669","article-title":"Cd19\/BCMA CAR-T cell therapy for refractory systemic lupus erythematosus-safety and preliminary efficacy data from a phase I clinical study","volume":"142","author":"Feng","year":"2023","journal-title":"Blood"},{"issue":"10S","key":"10.1016\/j.semarthrit.2025.152786_bib0018","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2024xhxtpbg3","article-title":"Safety and efficacy of low-dose CD19-targeted CAR T cells in refractory pediatric systemic Lupus erythematosus (SLE): SA-OR100","volume":"35","author":"He","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0019","article-title":"P101 Anti-CD19 CAR-T cell therapy for refractory childhood-onset systemic lupus erythematosus","author":"Marasco","year":"2024","journal-title":"Arch Dis Childhood;"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152786_bib0020","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in Autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2025.152786_bib0021","first-page":"null","article-title":"P95\u00e2 First two US patients with lupus nephritis (LN) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy: preliminary results from the KYSA-1 phase 1, multicenter study of KYV-101","volume":"11","author":"Amber","year":"2024","journal-title":"Lupus Sci Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152786_bib0022","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0023","doi-asserted-by":"crossref","unstructured":"Shu J., Xie W., Mei C., Ren A., Ke S., Ma M., et al. Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial. 2025 (2589-5370 (Electronic)).","DOI":"10.1016\/j.eclinm.2025.103229"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/s41422-025-01128-1","article-title":"Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus","author":"Yang","year":"2025","journal-title":"Cell Res."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0025","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","author":"Wang","year":"2025","journal-title":"Med."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0026","volume":"76","author":"Schett","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0027","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ard.2025.05.214","article-title":"OP0202\u2005Reset-sle: Clinical trial evaluating rese-cel (RESECABTAGENE AUTOLEUCEL), a fully HUMAN, autologous 4-1bb anti-Cd19 car t cell therapy in non-renal sle and lupus nephritis","volume":"84","author":"Sheikh","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0028","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ard.2025.05.396","article-title":"LB0009\u2005Allogenic Cd19 car Nk cell therapy in refractory systemic lupus erythematosus-a case series study","volume":"84","author":"Gao","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0029","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ard.2025.05.056","article-title":"OP0032\u2005Treatment of refractory systemic Lupus erythematosus with off-the-shelf iPSC-derived anti-CD19 CAR T-cell therapy","volume":"84","author":"Sandhu","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ard.2025.05.101","article-title":"OP0079\u2005Clinical, cellular kinetics, pharmacodynamics and biomarker data up to 12 months after YTB323 (Rapcabtagene Autoleucel), a rapidly manufactured CD19 CAR-T therapy, from an open-label, phase 1\/2 study in severe refractory SLE","volume":"84","author":"Morand","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0031","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ard.2025.05.096","article-title":"OP0074\u2005Preliminary results of CD19\/BCMA dual-targeting FasTCAR-T cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosus-an open-label, single-arm study","volume":"84","author":"Wu","year":"2025","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0032","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ard.2025.05.459","article-title":"POS0062\u2005Safety and preliminary efficacy of Cd19 car t-cell treatment in rheumatic disease \u2013 DATA from the phase I\/ii castle basket study","volume":"84","author":"Hagen","year":"2025","journal-title":"Ann. Rheum. Dis."},{"issue":"10437","key":"10.1016\/j.semarthrit.2025.152786_bib0033","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152786_bib0034","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic Lupus Erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"10468","key":"10.1016\/j.semarthrit.2025.152786_bib0035","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/S0140-6736(24)02265-7","article-title":"Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells","volume":"404","author":"Hagen","year":"2024","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152786_bib0036","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of Systemic Lupus Erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0037","article-title":"Allogenic CD19 CAR NK cells therapy in refractory systemic Lupus Erythematosus: an open-label, single arm, prospective and interventional clinical trial","volume":"2024","author":"Sun","year":"2024","journal-title":"ACR Convergence"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0038","article-title":"Development of next generation CAR T cell therapy for the off-the-shelf treatment of autoimmune diseases without conditioning chemotherapy [abstract]","author":"Goulding","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0039","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/annrheumdis-2024-eular.1768","volume":"83","author":"Cort\u00e9s-Hern\u00e1ndez","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0040","first-page":"76","article-title":"Safety and preliminary efficacy of CD19 CAR-T cell treatment in rheumatic disease \u2013 Data from the first part of the phase I\/II CASTLE basket study [abstract]","author":"Schett","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.semarthrit.2025.152786_bib0041","article-title":"Safety and efficacy of CABA-201, a fully human, autologous 4-1BB anti-CD19 CAR T cell therapy, in patients with active systemic lupus erythematosus: initial results of the phase 1\/2 RESET-SLE trial","author":"Sheikh","year":"2024","journal-title":"ACR Convergence Abstracts"},{"issue":"SUPPL 1","key":"10.1016\/j.semarthrit.2025.152786_bib0042","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/annrheumdis-2020-eular.4065","article-title":"First-in-human trial of bcma-cd19 compound car in the treatment of autoantibody mediated disorders","volume":"79","author":"Liu","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0043","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/annrheumdis-2024-eular.4073","article-title":"Bcma Cd19 compound chimeric antigen receptor t cells (cCAR) provides complete humoral reset, eliminates all elevated autoantibodies, improves symptoms and renal function in lupus nephritis (LN) patients","volume":"83","author":"Ma","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0044","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/blood-2023-180547","article-title":"CD19-Targeted CAR-T cells in refractory systemic autoimmune diseases: a monocentric experience from the first fifteen patients","volume":"142","author":"Mueller","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2022-eular.1120","article-title":"CAR-T CELL TREATMENT of REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS-SAFETY and PRELIMINARY EFFICACY DATA from the FIRST FOUR PATIENTS","volume":"81","author":"Schett","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0046","first-page":"A170","article-title":"Interim results of an open-label, multicentre, phase 1\/2 study to assess Ytb323 (RAPCABTAGENE AUTOLEUCEL), a car t-cell therapy, for severe refractory systemic lupus erythematosus","volume":"11","author":"Hern\u00e1ndez","year":"2024","journal-title":"Lupus Science and Medicine"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0047","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2023-eular.4161","article-title":"Novel approach to treat systemic lupus erythematosus, by targeting the root cause, B cells and plasma cells, using Bcma-Cd19 compound car","volume":"82","author":"Yuan","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0048","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1182\/blood-2022-165077","article-title":"CD19-Targeted CAR-T cells in refractory systemic Lupus Erythematosus: safety, efficacy, and mechanistic insights from the first five patients","volume":"140","author":"Mueller","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0049","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/annrheumdis-2023-eular.3736","article-title":"Long term safety and efficacy of car-t cell treatment in refractory systemic lupus erythematosus-data from the first seven patients","volume":"82","author":"Taubmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/annrheumdis-2024-eular.1478","article-title":"Long-term safety and efficacy of car-t cell treatment in severe and treatment refractory autoimmune disease","volume":"83","author":"Taubmann","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.semarthrit.2025.152786_bib0051","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2024-eular.3246","article-title":"An open-label, single arm, multicenter study to evaluate relmacabtagene autoleucel, the Cd-19 directed car-t cell therapy, for active systemic lupus erythematosus in China","volume":"83","author":"Hu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152786_bib0052","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152786_bib0053","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152786_bib0054","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0055","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","author":"Tur","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152786_bib0056","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152786_bib0057","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2025.152786_bib0058","series-title":"The ebmt\/eha car-t cell handbook [Internet]","article-title":"Management of Immune Effector cell-Associated Neurotoxicity Syndrome (ICANS)","author":"Rees","year":"2022"},{"issue":"Supplement 1","key":"10.1016\/j.semarthrit.2025.152786_bib0059","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1182\/blood-2023-188830","article-title":"CAR-T cell therapy in patients with refractory systemic autoimmune diseases exhibits less inflammation, toxicities and different cellular dynamics compared to patients with B cell lymphoma","volume":"142","author":"Mueller","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152786_bib0060","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41409-020-0956-8","article-title":"Value and affordability of CAR T-cell therapy in the United States","volume":"55","author":"Fiorenza","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"19","key":"10.1016\/j.semarthrit.2025.152786_bib0061","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191912366","article-title":"Price and prejudice? The value of chimeric antigen receptor (CAR) T-cell therapy","volume":"19","author":"Choi","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152786_bib0062","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152786_bib0063","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152786_bib0064","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722500157X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722500157X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:01:43Z","timestamp":1780120903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722500157X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":63,"alternative-id":["S004901722500157X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152786","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy in SLE: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152786","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152786"}}